OV350 showed a good safety profile, supporting the advancement of the Company’s KCC2 portfolio, including the first oral ...
In patients without diabetes, sodium–glucose cotransporter-2 (SGLT2) inhibitors (or “flozins”) should be considered for moderate chronic kidney disease or clinical heart failure regardless of ejection ...
We thank Dr. Mithoowani and colleagues for their excellent review on the investigation and management of erythrocytosis,1 which provides a comprehensive overview and approach to a common presentation ...
The effects of empagliflozin, an inhibitor of sodium–glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high ...
About The Study: In this study of discharge prescription of a sodium-glucose cotransporter-2 inhibitor (SGLT2i) among patients hospitalized for heart failure, prescription rates increased ...
Spain: Researchers have found in a new study that sodium-glucose cotransporter-2 (SGLT-2) inhibitors have a neutral effect on ...
In a recent study published in Engineering, a team of researchers led by Wenyu Zhang from South China Agricultural University has developed a groundbreaking cotransporter system that combines a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback